Arthrogenic alphavirus vaccine
AssigneeGriffith University
InventorsSurendran Mahalingam, Adam Taylor
Life of this patent
Estimating the term…
Abstract
The invention relates to a vaccine comprising live attenuated recombinant alphavirus comprising mutated capsid protein. The invention also relates to a method of preventing a subject from contracting an alphaviral infection that would otherwise produce clinical signs of disease. In an embodiment the mutated capsid protein is Chikungunya virus (CHIKV) capsid protein having a mutated nucleolar localisation signal/sequence (NoLS), preferably the mutant NLS 101/95.
Claims9
A vaccine selected from the group consisting of:
- (a) an isolated, purified, synthetic or recombinant Chikungunya virus (CHIKV) mutated capsid protein;
- (b) an isolated, purified, synthetic or recombinant CHIKV nascent structural polyprotein comprising a mutated CHIKV capsid protein;
- (c) a recombinant CHIKV genome encoding a mutated CHIKV capsid protein;
- (d) a recombinant CHIKV comprising a mutated CHIKV capsid protein;
- (e) a live attenuated recombinant CHIKV comprising a mutated CHIKV capsid protein;
- (f) a chimeric alphavirus comprising a mutated CHIKV capsid protein;
- (g) a live attenuated chimeric alphavirus comprising a mutated CHIKV capsid protein;
- and
- (h) an inactivated attenuated recombinant CHIKV comprising a mutated CHIKV capsid protein,
- wherein the mutated CHIKV capsid protein has at least a mutated nucleolar localization region (NoLS) compared with wildtype CHIKV capsid protein and is incapable or substantially incapable of nucleolar localization, and
- wherein:
- the mutated CHIKV capsid protein comprises at least amino acid positions 62, 63, 65, 66, 68, 69, 101 and 102 of wild-type CHIKV capsid protein shifted in position, replaced and/or deleted, and wherein the corresponding region of wild-type CHIKV capsid protein is shown in SEQ. ID NO. 3;
- or
- the mutated NoLS sequence is selected from the group consisting of SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6 and SEQ. ID NO. 7.
A vaccine or sub-unit vaccine selected from the group consisting of a recombinant CHIKV comprising a mutated CHIKV capsid protein, a recombinant CHIKV nascent structural polyprotein comprising a mutated CHIKV capsid protein, and a recombinant CHIKV genome encoding a mutated capsid protein, wherein the mutated CHIKV capsid protein is a nucleolar localization region (NoLS) mutant of wild-type CHIKV capsid protein incapable or substantially incapable of nucleolar localization, and wherein:
- the mutated CHIKV capsid protein comprises at least amino acid positions 62, 63, 65, 66, 68, 69, 101 and 102 of wild-type CHIKV capsid protein shifted in position, replaced and/or deleted, and wherein the corresponding region of wild-type CHIKV capsid protein is shown in SEQ. ID NO. 3;
- or
- the mutated NoLS sequence is selected from the group consisting of SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6 and SEQ. ID NO. 7.
Dependencies are inferred from the claim text.